Shares of Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 8700 shares traded. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Price Performance
The company has a quick ratio of 0.46, a current ratio of 0.07 and a debt-to-equity ratio of 138.88. The company has a 50 day moving average price of C$0.01 and a 200-day moving average price of C$0.02. The company has a market cap of C$663,150.00, a price-to-earnings ratio of -0.50 and a beta of -0.02.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- How to Use High Beta Stocks to Maximize Your Investing Profits
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Election Stocks: How Elections Affect the Stock Market
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Technology Stocks Explained: Here’s What to Know About Tech
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
